Skip to main content

Advertisement

SpringerLink
Log in

Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma entity exhibiting peculiar clinical features and poor prognosis. Its clinical characteristics and prognostic factors are not well established. To clarify the clinical characteristics and prognostic features of AITL, we conducted a multicenter, retrospective study. Fifty-six patients were enrolled. The median patient age was 68 years. Immunohistochemical examinations of tumor cells showed positivity for CD10 and T-cell markers, and chromosomal examination detected several types of abnormalities. More than 80 % of patients show advanced disease at diagnosis and poor prognostic scores. A high proportion of patients showed accompanying B symptoms, splenomegaly, and hepatomegaly at diagnosis. The 5-year overall survival (OS) rate was 48 % and progression-free survival was 25 %. Univariate analysis revealed higher age, fever, poor performance status, anemia, and low albumin level to be poor prognostic factors for OS. In addition to these factors, both IPI and PIT were also predictive of OS. Multivariate analysis indicated only a low level of serum albumin to be a significant prognostic factor for OS. Serum albumin may be one of the important prognostic factors for AITL. Further investigation is needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.

    Article  PubMed  Google Scholar 

  3. de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63.

    Article  PubMed  Google Scholar 

  4. Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.

    Article  CAS  PubMed  Google Scholar 

  5. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.

    Article  PubMed  Google Scholar 

  6. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.

    Article  CAS  PubMed  Google Scholar 

  9. Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364–70.

    Article  CAS  PubMed  Google Scholar 

  10. Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892–5.

    CAS  PubMed  Google Scholar 

  11. Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601–3.

    Article  CAS  PubMed  Google Scholar 

  12. Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.

    CAS  PubMed  Google Scholar 

  13. Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659–64.

    CAS  PubMed  Google Scholar 

  14. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.

  15. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    Article  CAS  PubMed  Google Scholar 

  16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.

    CAS  PubMed  Google Scholar 

  17. Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

    CAS  PubMed  Google Scholar 

  20. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.

    Article  CAS  PubMed  Google Scholar 

  21. Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813–21.

    Article  CAS  PubMed  Google Scholar 

  22. Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12–20.

    Article  CAS  PubMed  Google Scholar 

  23. Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983;52:318–21.

    Article  CAS  PubMed  Google Scholar 

  24. Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987;59:208–12.

    Article  CAS  PubMed  Google Scholar 

  25. Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma. Bone Marrow Transpl. 1999;24:271–7.

    Article  CAS  Google Scholar 

  26. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood. 2000;95:783–9.

    CAS  Google Scholar 

  27. Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.

    Article  CAS  PubMed  Google Scholar 

  28. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.

    Article  CAS  PubMed  Google Scholar 

  29. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors appreciate the collaboration of all members of the Tohoku Hematology Forum and the collaboration of all participants.

Conflict of interest

The authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Hematology, Akita University, Akita, Japan

    Yoshihiro Kameoka, Naoto Takahashi, Hiroyuki Tagawa & Kenichi Sawada

  2. Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan

    Shigeki Itou & Yoji Ishida

  3. Department of Internal Medicine, Hiraka General Hospital, Yokote, Japan

    Masaaki Kume

  4. Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan

    Hideyoshi Noji

  5. Department of Hematology, Yamagata University, Yamagata, Japan

    Yuichi Kato

  6. Department of Internal Medicine, Akita City Hospital, Akita, Japan

    Yoshikazu Ichikawa

  7. Department of Hematology, Miyagi Cancer Center, Natori, Japan

    Osamu Sasaki

  8. Department of Internal Medicine, Senboku Hospital, Daisen, Japan

    Mutsuhito Motegi

  9. Department of Oncology, Hirosaki University, Hirosaki, Japan

    Atsushi Ishiguro

  10. Department of Hematopathology, Tohoku University, Sendai, Japan

    Kenichi Ishizawa, Ryo Ichinohasama & Hideo Harigae

  11. Division of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, 44-2 Hasunuma Hiroomote, Akita City, Akita, 010-0041, Japan

    Yoshihiro Kameoka

Authors
  1. Yoshihiro Kameoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoto Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Itou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaaki Kume
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideyoshi Noji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuichi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshikazu Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Osamu Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mutsuhito Motegi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Atsushi Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroyuki Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kenichi Ishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoji Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ryo Ichinohasama
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hideo Harigae
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Kenichi Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Kameoka.

Additional information

On behalf of the Tohoku Hematology Forum.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kameoka, Y., Takahashi, N., Itou, S. et al. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. Int J Hematol 101, 536–542 (2015). https://doi.org/10.1007/s12185-015-1763-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1763-7

Keywords

Search

Navigation